Tempus and Stemline Therapeutics, Inc., A Subsidiary of the Menarini Group, Announce Collaboration to Implement Tempus Next, an AI-Enabled Care Pathway Intelligence Platform to Support Patients with M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. DFTX
10. NKE

Go back to Tempus and Stemline Therapeutics, Inc., A Subsidiary of the Menarini Group, Announce Collaboration to Implement Tempus Next, an AI-Enabled Care Pathway Intelligence Platform to Support Patients with M

Stifel Reiterates Hold Rating on Tempus AI Inc (TEM)

February 25, 2025 9:09 AM EST

Stifel analyst Daniel Arias reiterated a Hold rating and $65.00 price target on Tempus AI Inc (NASDAQ: TEM).

The analyst comments "4Q results were in line with the JPM pre-announcement, as revenues grew 36%. For FY25, the full business (core TEM + Ambry) matches... More

JPMorgan Downgrades Tempus AI Inc (TEM) to Neutral

February 25, 2025 5:13 AM EST

JPMorgan analyst Rachel Vatnsdal downgraded Tempus AI Inc (NASDAQ: TEM) from Overweight to Neutral with a price target of $55.00 (from $50.00).

The analyst comments "Tempus AI (TEM) reported 4Q results in-line with the pre-announcement from our conference (where revenue slightly missed expectations on non-core business weakness) while lifting its 2025 guidance, now calling for 2025 revenue of ~$1.24B inclusive of 11 months of Ambry (which closed on Feb. 3rd) vs. prior guide of ~$1.23B, along with adj. EBITDA of $5M this year vs.... More